Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cyteir Therapeutics, Inc. CYT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
25/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$2.00
-33.8%

Cyteir Therapeutics, Inc. (CYT) is a Biotechnology company in the Healthcare sector, currently trading at $3.02. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is CYT = $2 (-33.8% upside).

Net income is $44M (loss), growing at -48%/yr. Net profit margin is 0% (thin). Gross margin is -58.6% (+0 pp trend).

Balance sheet: total debt is $889,000 against $146M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 28.07 (strong liquidity). Debt-to-assets is 0.6%. Total assets: $153M.

Analyst outlook: 2 / 5 analysts rate CYT as buy (40%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 11/100 (Fail), Future 16/100 (Fail), Income ?/100 (Fail).

$2.00
▼ 33.77% Downside
Average Price Target
The 12-month price target for Cyteir Therapeutics, Inc. is $2.00.

CYT SharesGrow Score Overview

30/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 11/100
Gross margin is + market cap
FUTURE 16/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CYT

✗
VALUE Fail
10/100
CYT trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $2, implying -33.8% from the current price $3. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
CYT: -100%/yr revenue is, -48%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet CYT: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 28.07 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
11/100
CYT: Gross margin is -58.6% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 11/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
16/100
Analyst outlook: 2 / 5 analysts rate CYT as buy (40%). Analyst consensus target is $2 (-33.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.65-3.19
Volume1.01M
Avg Volume (30D)167.62K
Market Cap$108.71M
Beta (1Y)0.10
Share Statistics
EPS (TTM)-1.25
Shares Outstanding$35.27M
IPO Date2021-06-18
Employees46
CEOMarkus F. Renschler
Financial Highlights & Ratios
Gross Profit$-1.38M
EBITDA$-47.5M
Net Income$-43.95M
Operating Income$-48.17M
Total Cash$147.12M
Total Debt$889K
Net Debt$-146.23M
Total Assets$153.23M
Price / Earnings (P/E)-2.4
Analyst Forecast
1Y Price Target$2.00
Target High$2.00
Target Low$2.00
Upside-33.8%
Rating ConsensusBuy
Analysts Covering5
Buy 40% Hold 20% Sell 40%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS23284P1030

Price Chart

Track all markets on TradingView
CYT
Cyteir Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.65 52WK RANGE 3.19

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.82
-0.72%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$18.23
+4.17%
 SANA
SANA
Sana Biotechnology, Inc.
$3.44
-1.15%
 LYEL
LYEL
Lyell Immunopharma, Inc.
$23.84
+2.01%
 RZLT
RZLT
Rezolute, Inc.
$3.59
+1.13%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 PRLD
PRLD
Prelude Therapeutics Incorporated
$5.52
+25.45%
 FHTX
FHTX
Foghorn Therapeutics Inc.
$4.87
+0.41%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message